A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)-Reference-Cited by-同舟云学术

A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)

Published:2021-11 Issue: Volume:158 Page:169-180
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Campone Mario,Bachelot Thomas^ORCID,Treilleux Isabelle,Pistilli Barbara,Salleron Julia^ORCID,Seegers Valérie,Arnedos Monica,Loussouarn Delphine,Wang Qing,Vanlemmens Laurence,Jimenez Marta^ORCID,Rios Maria,Diéras Véronique,Leroux Agnès,Paintaud Gilles^ORCID,Rezai Keyvan,André Fabrice,Lion Maëva,Merlin Jean-Louis^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;N Engl J Med,2005

3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med,2005

4. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies;Lewis;Cancer Immunol Immunother,1993

5. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2;Gennari;Clin Cancer Res,2004

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer;eLife;2023-09-29

2. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30

3. HER2-positive breast cancer: cotargeting to overcome treatment resistance;Current Opinion in Oncology;2023-07-06

4. New Drug Discovery;Multidisciplinary Applications of Natural Science for Drug Discovery and Integrative Medicine;2023-06-16

5. Evaluating everolimus for the treatment of breast cancer;Expert Opinion on Pharmacotherapy;2023-05-18